T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.
The popularity of nonreplicating adenoviruses of chimpanzee origin (ChAdVs) as vectors for subunit vaccines is on the rise. This is mainly for their excellent safety and impressive immunogenicity observed in human studies to date. Here, we recloned the chimpanzee adenovirus sero type 68 (ChAdV-68),...
Main Authors: | Roshorm, Y, Cottingham, MG, Potash, M, Volsky, D, Hanke, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
by: Nébié, I, et al.
Published: (2014) -
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
by: Warimwe, G, et al.
Published: (2013) -
Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge.
by: Roshorm, Y, et al.
Published: (2009) -
Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV.
by: Kelschenbach, J, et al.
Published: (2012) -
Mice Chronically Infected with Chimeric HIV Resist Peripheral and Brain Superinfection: A Model of Protective Immunity to HIV
by: Kelschenbach, J, et al.
Published: (2011)